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Abstract
Background—Reporting ototoxicity is frequently complicated by use of various ototoxicity
criteria. The International Society of Pediatric Oncology (SIOP) ototoxicity grading scale was
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recently proposed for standardized use in reporting hearing loss outcomes across institutions. The
aim of this study was to evaluate the concordance between the Chang and SIOP ototoxicity
grading scales. Differences between the two scales were identified and the implications these
differences may have in the clinical setting were discussed.
Procedure—Audiological evaluations were reviewed for 379 patients with newly diagnosed
medulloblastoma (ages 3–21 years). Each patient was enrolled on one of two St. Jude clinical
protocols that included craniospinal radiation therapy and four courses of 75 mg/m2 cisplatin
chemotherapy. The latest audiogram conducted 5.5 – 24.5 months post-protocol treatment
initiation was graded using the Chang and SIOP ototoxicity criteria. Clinically significant hearing
loss was defined as Chang grade ≥ 2a and SIOP ≥2. Hearing loss was considered serious
(requiring a hearing aid) at the level of Chang grade ≥ 2b and SIOP ≥ 3.
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Results—A strong concordance was observed between the Chang and SIOP ototoxicity scales
(Stuart’s tau-c statistic = 0.89, 95% CI: 0.86, 0.91). Among those patients diagnosed with serious
hearing loss, the two scales were in good agreement. However, the scales deviated from one
another in classifying patients with less serious or no hearing loss.
Conclusions—Although discrepancies between the Chang and SIOP ototoxicity scales exist
primarily for patients with no or minimal hearing loss, the scales share a strong concordance
overall.
Keywords
ototoxicity; hearing loss; cisplatin; late effects; medulloblastoma
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Cisplatin is frequently used in chemotherapy regimens to treat a variety of pediatric solid
and central nervous system malignancies. Unfortunately, ototoxicity is a potential adverse
effect of cisplatin use, typically resulting in permanent bilateral sensorineural hearing loss,
first in the high frequency region then extending to the lower frequencies with continued
exposure [1–3]. Younger children are at greater risk for developing permanent hearing loss
from cisplatin exposure compared to older children [4], which can lead to significant delays
in speech, language, and social development [5]. Loss of hearing in the high frequency range
diminishes the ability to hear and recognize certain phonemes, primarily fricatives, which
are important for the development and comprehension of speech, particularly for young
children [6]. Even mild degrees of hearing impairment can negatively impact
communication, academic performance, and psychosocial outcomes in young children [7,
8]. Because early detection of hearing loss and early intervention in infants and children are
essential for optimizing speech, language, and social-emotional development [9–11],
implementing a clinically relevant grading scale sensitive to identifying high frequency
hearing loss in young patients receiving ototoxic drugs is an important component to
successfully managing these patients [12].
The assessment of ototoxicity in patients has become more objective with the establishment
of ototoxicity monitoring protocols [13–17] and hearing loss grading scales [1, 2, 18–22].
Several ototoxicity grading schemes have been proposed over the past two decades for
Pediatr Blood Cancer. Author manuscript; available in PMC 2015 April 01.

Bass et al.

Page 3

Author Manuscript

various purposes, such as classifying hearing loss severity [2], identifying early changes in
hearing sensitivity [18, 19], correlating hearing loss classifications to functional outcomes
[19, 20], and reporting ototoxicity as an adverse event in oncologic clinical trials [1, 21, 22].
The purpose of a grading scale is to objectively define and report ototoxicity. However, the
implementation of different ototoxicity grading scales across institutions has made analyzing
ototoxicity studies challenging to interpret and has contributed to the variability in reporting
the prevalence of platinum-associated hearing loss throughout the literature [23].
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Recent attempts have been made to create a standardized ototoxicity scale that could be
widely adapted in pediatric oncology settings. In 2010, Chang and Chinosornvatana
proposed an ototoxicity grading scale based on absolute hearing threshold levels that better
correlated hearing loss categories to clinical recommendations compared to the Common
Terminology Criteria for Adverse Events (CTCAE) grading criteria currently used in many
clinical trials [20]. The Chang scale was developed as a modification to the frequently-used
Brock ototoxicity scale, a scale developed specifically for children receiving cisplatin
chemotherapy [2]. The Chang scale detected milder degrees of hearing loss and better
correlated with functional outcomes compared to the Brock scale [20]. The Chang scale
represents typical grading scales often used by the medical community to report adverse
events. Toxicity scales typically consist of 5 levels of severity, ranging from 0 (no
complications) to 4 (severe complications). Chang divided grades 1 and 2 into grades 1a, 1b,
2a, and 2b to more precisely distinguish between different degrees of functional hearing
loss; however this resulted in a scale which exceeded the typical 5 levels of severity
customarily seen in toxicity grading. In 2012, a panel of experts published the SIOP
ototoxicity grading scale for the purpose of comparing end-of-treatment hearing loss in
oncologic clinical trials across institutions [1]. The SIOP scale, a modification of the
Children’s Hospital of Boston functional hearing loss scale [19], is based on absolute
hearing threshold measurements and is sensitive to high frequency hearing loss and mild
degrees of impairment while retaining the customary 5 levels of severity [1]. We chose to
compare the Chang and SIOP ototoxicity scales as they both represent improvements upon
existing scales and reliability and validity measures have yet to be reported for the SIOP
scale. The purpose of this study was to evaluate concordance between the Chang and the
SIOP ototoxicity grading scales and identify areas of disparity between the two scales.
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Methods

Patient Characteristics
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The source population for this study was patients newly-diagnosed with average or high risk
medulloblastoma treated on either the SJMB96 or SJMB03 treatment protocols at St. Jude
Children’s Research Hospital (SJCRH) or one of the nine collaborative study sites. Informed
consent was obtained from all parents or guardians of study participants and both clinical
protocols were approved by the Human Subjects Institutional Review Boards at St. Jude
Children’s Research Hospital and each of the participating institutions. Gajjar et al [24] and
Fouladi et al [25] previously described eligibility criteria and course of therapy for the
SJMB96 and SJMB03 protocols. Briefly, eligibility for these protocols included patients
with newly diagnosed medulloblastoma aged 3–21 years having received no prior
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chemotherapy or radiotherapy. Protocol treatment included a surgical resection, six weeks of
craniospinal radiation therapy, and chemotherapy. Average and high risk patients received
23.4 Gy and 36–39.6 Gy craniospinal radiotherapy, respectively with 55.8 Gy to the primary
tumor bed. The clinical target volume of the boost dose to the tumor bed was reduced from
2.0 cm in the SJMB96 protocol to 1.0 cm in the SJMB03 protocol. The chemotherapy
regimen for these patients consisted of four cycles of cyclophosphamide, vincristine,
cisplatin, and stem cell or bone marrow rescue. Cisplatin dose included 75 mg/m2 each cycle
totaling 300 mg/m2 cumulative dose. The SJMB96 protocol began enrolling patients in
October 1996 and was amended in August 1999 to include amifostine [25], a thiophosphate
cytoprotective agent given to reduce toxicities associated with radiotherapy and alkylating
and platinum-containing agents [26]. Amifostine was administered immediately prior to and
again three hours into each of the four cycles of cisplatin treatments to minimize ototoxic
effects [25]. Audiometric evaluations were included as standard of care in both protocols.
Eligibility for this analysis was limited to patients diagnosed with medulloblastoma from
September 1996 to March 2012 who received at least one audiometric evaluation between
5.5–24.5 months from initiation of protocol-based treatment. Patients who did not receive
cisplatin chemotherapy and those with permanent hearing loss in at least one ear at baseline
were excluded from this analysis.
Audiological Methods
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Various audiological testing methods were used to assess hearing dependent upon the
patient’s age, cognitive and developmental abilities, and level of cooperation.
Tympanometry was reviewed to determine the integrity of the conductive mechanism at the
time of testing. Pure-tone air conduction thresholds were evaluated at frequencies 0.25, 0.5,
1, 2, 3, 4, 6, and 8 kHz in decibel (dB) hearing level (HL). Pure tone bone conduction
thresholds were assessed at frequencies 0.25, 0.5, 1, 2, 3, and 4 kHz to determine the nature
of the hearing impairment (i.e., conductive, sensorineural, or mixed). Click and tone-burst
auditory brainstem response (ABR), auditory steady-state response, and/or distortionproduct otoacoustic emissions (DPOAE) measurements were evaluated on patients who
were unable to participate in conventional audiometric testing due to young age, cognitive or
developmental delay, or lack of cooperation. The ototoxicity monitoring schedule consisted
of an evaluation at the following time points: baseline (occurred within 2 weeks of initiation
of radiation therapy), prior to each high dose cisplatin chemotherapy cycle, and at 9, 12, 15,
and 24 months following diagnosis. Audiometric data from St. Jude and the nine
collaborative sites were reviewed and assigned an ototoxicity grade by a single research
audiologist at St. Jude (JKB). Each audiological evaluation was given an ototoxicity grade
based on the Chang Ototoxicity Grading Scale [20] and the International Society of Pediatric
Oncology Ototoxicity Scale (Table I) [1]. The latest audiometric evaluation that occurred
between 5.5–24 months from on-treatment date was used for the analysis.
Statistical approach
The objective of the statistical analysis was to evaluate the concordance in hearing levels
between the Chang and SIOP scales. If hearing levels were asymmetrical, the level in the
worst ear was used for the analysis. The Stuart’s tau-c statistic for testing association of two
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ordinal scales among non-square contingency tables was used as a measure of concordance
[27].

Results
Patient enrollment
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A total of 452 patients diagnosed with medulloblastoma were enrolled on either the SJMB96
(n=134) or SJMB03 (n=318) protocol as of March 2012. Of these, 418 patients diagnosed
with medulloblastoma met eligibility criteria for having at least one audiology assessment
between 5.5–24.5 months from treatment onset. Patients with non-transient hearing loss in at
least one ear at baseline (n=35) or patients who did not receive cisplatin (n=4) were
excluded from this analysis. Of the 379 evaluable patients, the median cumulative cisplatin
dose was 300 mg/m2 (range 74–329 mg/m2). The median time from initiation of treatment
to the latest audiological evaluation was 19.1 months. Table II provides an overview of the
patient characteristics.
Concordance between Chang and SIOP
Table III compares the number of patients in each hearing level of the Chang and SIOP
scales. Based on these data, the Stuart’s tau-c statistic was estimated to be 0.89 (95% CI:
0.86, 0.91), indicating a very strong concordance.
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Figure 1b compares the percentage of patients coded as having clinically significant hearing
loss versus minimal or no hearing loss between the Chang and SIOP grading criteria. We
considered “clinically significant hearing loss” as Chang grade ≥2a or SIOP grade≥ 2. Using
the Chang scale, 156 (41%) patients were coded as having clinically significant hearing loss
versus 183 (48%) coded with SIOP. For the 51 patients with a SIOP grade 2 hearing loss, 27
(53%) were coded as having a lesser grade by Chang grade 1b.
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As shown in Figure 1a, the prevalence of any detectable hearing loss was 66% and 74%
according to the Chang and SIOP scales, respectively. Among the 128 patients coded as
having no hearing loss (grade 0) based on the Chang criteria, 30 (23%) were categorized as
having SIOP grade 1, indicating non-concordance between the scales for some degree of
high frequency hearing loss (Table III).

The scales were in better agreement in identifying more severe hearing impairment as
evident in Figure 1c. For both scales, 132 (35%) patients were coded as having serious
hearing loss requiring amplification. Minor differences were noted between the scales in
defining grade 3 and 4 ototoxicity. Of the 95 patients assigned a Chang grade 3 hearing loss,
21 (22%) were classified by SIOP as grade 4. For grade 3 hearing loss, SIOP (n=100, 26%)
and Chang (n=95, 25%) were similar in coding; however, for grade 4, SIOP coded 20 more
patients (n=32, 8%) than Chang (n=12, 3%). As seen in Table III, one patient was classified
as a SIOP grade 3 and Chang grade 4. This finding was unusual given that the SIOP criteria
are more sensitive in defining grade 4 hearing loss compared to the Chang scale. This
patient’s hearing threshold for 2 kHz was slightly better compared to 1 kHz, which is an
atypical configuration for cisplatin-induced hearing loss and is considered a rare occurrence.
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However, this example represents a potential, albeit uncommon, disagreement between the
Chang and SIOP scales for patients with serious hearing loss.

Discussion
We compared hearing loss levels in 379 pediatric patients with medulloblastoma who
received high-dose cisplatin using two recently published ototoxicity grading scales, the
SIOP and Chang scale. We observed an overall high degree of concordance between the two
scales, particularly in classifying serious hearing loss requiring hearing aids. However,
important differences were observed for mild and clinically significant degrees of hearing
impairment.
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The SIOP scale was more sensitive than the Chang scale in detecting mild levels of high
frequency hearing loss. The definition for SIOP grade 1 hearing loss is 20 dB lower than
Chang grade 1a, thus classifying milder forms of hearing loss between 25–35 dB HL as an
ototoxic occurrence. Because the SIOP scale uses a lower hearing level threshold to define
grade 1 hearing loss, it may be more sensitive than the Chang criteria for identifying any
incidence of ototoxicity. However, if the goal is to identify serious ototoxicity as an adverse
event, it appears there is no benefit of using the SIOP over the Chang scale.
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For this study, we considered Chang grade 2a and SIOP grade 2 as “clinically significant,”
indicating intervention such as preferential classroom seating, additional educational
accommodations, and/or use of assistive technology (i.e., FM system) but not requiring the
use of hearing aids. Identifying children with clinically significant hearing loss is important
as mild hearing impairment may result in significant language and academic deficits [7, 8].
A notable difference exists between the Chang and SIOP criteria in classifying patients with
clinically significant hearing loss. Essentially half (53%) of SIOP grade 2 patients were
coded with a milder Chang grade 1b. Again, the reason for this discrepancy is the difference
in decibel level used to define each grade level between the two scales. SIOP grade 2 uses a
lower decibel value of ≥25 dB compared to the Chang 2a decibel value of ≥40 dB. Thus,
SIOP grade 2 is more sensitive in detecting patients with clinically significant hearing loss.
Chang 2a was found to be the level of hearing loss that most corresponded to patients
receiving FM systems [20]. The lower decibel threshold for SIOP grade 2 probably includes
some patients who do not need an FM system.
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Although Chang and SIOP ototoxicity outcomes were somewhat discrepant in patients
experiencing milder degrees of high frequency hearing loss, the scales were congruent in
identifying more severe hearing impairment. Patients diagnosed with a Chang grade≥2b or
SIOP grade ≥3 hearing loss have serious hearing loss, typically requiring the use of hearing
aids, other assistive listening technology, educational resources, and additional
communicative strategies. While Chang grade ≥2b and SIOP grade ≥3 criteria identified the
same number of patients (n=131, 34.6%) as having serious hearing loss, minor differences
were noted between the scales in defining grade 4 ototoxicity. Overall, more patients were
coded as having grade 4 hearing loss based on the SIOP scale (n=32, 8.4%) compared to the
Chang scale (n=12, 3.2%). These two scales differ considerably in their definition for grade
4 hearing loss. As seen in Table I, grade 4 ototoxicity for SIOP indicates at least a moderate
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degree of hearing loss at ≥2 kHz while Chang grade 4 lowers the frequency range to include
moderate hearing loss at ≥1 kHz. The difference between these two scales in defining grade
4 hearing loss may be inconsequential in most cases with the exception for reporting
functional outcomes in oncologic clinical trials, particularly if a new drug or otoprotective
agent were being investigated. In this case, differentiating between grade 3 and 4 may be
valuable when evaluating adverse effects of a novel therapy or efficacy of an otoprotective
drug.
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Chang and Chinosornvatana [20] validated the Chang scale using the CTCAE v.3 criteria
and demonstrated a strong correlation between grading and hearing aid recommendation
using both scales; however, the Chang scale was more specific in predicting intervention
(hearing aid or FM system recommendation) for the more severe grades compared to the
CTCAE criteria making the Chang scale more clinically useful and relevant. The SIOP
ototoxicity grading scale was created using the best attributes from all of the existing scales
for the purpose of reporting end-of-treatment outcomes in clinical trials [1]. Although the
SIOP grades have not been correlated with hearing loss recommendations, the strong
concordance between Chang grades 2b-4 and SIOP grades 3–4 indicates that patients with
SIOP grades 3 and 4 ototoxicity would likely need hearing aids at the end of therapy.
The authors proposed international consensus and use of the SIOP scale, given positive
validation results. Our results indicate that the SIOP scale is reliable and clinically relevant
in classifying patients with ototoxic hearing loss and predicting functional outcomes and
clinical recommendations. The SIOP scale is easier to use and understand and is more
sensitive in detecting mild hearing loss compared to the Chang scale, supporting its
acceptance as the international ototoxicity grading scale.
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Strengths of this study include a large sample size, a population homogenous for cisplatin
exposure and high-quality, standardized treatment and ototoxicity monitoring protocols.
However, study limitations should be considered when interpreting our results. Our
population consisted of patients diagnosed with medulloblastoma with no other disease
groups represented. Our patients also received cranial radiation therapy prior to
chemotherapy, which has been shown to behave synergistically to exacerbate hearing loss
when paired with cisplatin chemotherapy [28]. Finally, most of the patients (87%) in our
cohort received amifostine to reduce or prevent hearing loss.
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In summary, we found strong concordance between the SIOP and Chang ototoxicity scales,
particularly for patients with serious hearing loss. Meaningful discrepancies exist between
the scales; mainly the SIOP scale is more sensitive in coding patients with milder degrees of
hearing loss. Recent advancements in cancer treatment, otoprotection, and genetic-related
ototoxicity studies support the need for a standardized, widely-accepted ototoxicity grading
scale, such as the SIOP scale, that would allow for easier grading and more consistent
outcome measures across institutions.
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Figure 1.
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Prevalence of hearing loss by Chang and SIOP scales. A: Any detected hearing loss. B:
Clinically significant hearing loss. C: Hearing loss requiring hearing aids.
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Ototoxicity Grading Scales*
Chang

SIOP

Grade 0

≤ 20 dB at 1, 2, and 4 kHz

Grade 0

≤20 dB HL at all frequencies

Grade 1a
Grade 1b

≥ 40 dB at any freq 6 to 12 kHz
> 20 and < 40 dB at 4kHz

Grade 1

>20 dB HL (i.e. 25 dB HL or greater) SNHL above 4000 Hz (i.e. 6 or 8
kHz)

Grade 2a
Grade 2b

≥ 40 dB at 4 kHz and above
> 20 and < 40 dB at any freq below 4kHz

Grade 2

>20 dB HL SNHL at 4000 Hz and above

Grade 3

≥ 40 dB at 2 or 3 kHz & above

Grade 3

>20 dB HL SNHL at 2000 Hz or 3000 Hz and above

Grade 4

≥ 40 dB at 1 kHz and above

Grade 4

>40 dB HL (i.e. 45 dB HL or more) SNHL at 2000 Hz and above

*

Sensorineural Hearing Threshold (dB HL) bone conduction or air conduction with normal tympanogram
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Patient Characteristics
Characteristic

n (%) (n = 379)
Male

243 (64%)

Female

136 (36%)

White

293 (77%)

Non-white

86 (23%)

Median

8.2

Gender

Race

Age at diagnosis (years)

Age at latest audiogram (years)
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Time from treatment initiation to latest audiogram (months)

Range

3.0–21.6

Interquartile Range

6.2 – 10.9

Median

9.7

Range

3.7 – 22.5

Interquartile Range

7.6 – 12.4

Median

19.1

Range

5.6 – 24.5

Interquartile Range

12.4 – 22.6

Average

263 (69%)

High

116 (31%)

SJMB03

266 (70%)

SJMB96

113 (30%)

Disease Risk

Study
St. Jude

192 (51%)

Collaborative site

187 (49%)

No

51(13%)

Yes

328 (87%)

Institution

Amifostine

Author Manuscript

Cisplatin cumulative dose (mg/m2)

Median

300

Range

74 – 329

Interquartile Range

295 – 302
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Author Manuscript

Author Manuscript

68

0

0

0

68

30

0

0

0

128

2

3

4

Total

0

0

1

1a

0

98

SIOP

27

0

0

27

0

0

1b

24

0

0

24

0

0

2a

25

0

25

0

0

0

2b

Chang

95

21

74

0

0

0

3

Table of SIOP by Chang

12

11

1

0

0

0

4

379

32

100

51

98

98

Total

Author Manuscript

Frequency comparison of SIOP vs. Chang hearing loss grades
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